Trial · NCT02850016
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Days to Viral Rebound During Analytical Treatment Interruption (ATI) | Group A | 18 | Inter-Quartile Range 14 to 28 | days | |
| Days to Viral Rebound During Analytical Treatment Interruption (ATI) | Group B | 28 | Inter-Quartile Range 21 to 35 | days | |
| Number of of Adverse Events (AE), Serious Adverse Events (SAE), and Serious Unexpected Serious Adverse Reactions (SUSAR). | Group A | All Adverse events related to Romidepsin | 112 | events | |
| Number of of Adverse Events (AE), Serious Adverse Events (SAE), and Serious Unexpected Serious Adverse Reactions (SUSAR). | Group B | All Adverse events related to Romidepsin | 66 | events | |
| Number of of Adverse Events (AE), Serious Adverse Events (SAE), and Serious Unexpected Serious Adverse Reactions (SUSAR). | Group A | All Adverse events related to 3BNC117 | 4 | events | |
| Number of of Adverse Events (AE), Serious Adverse Events (SAE), and Serious Unexpected Serious Adverse Reactions (SUSAR). | Group B | All Adverse events related to 3BNC117 | 0 | events | |
| Number of of Adverse Events (AE), Serious Adverse Events (SAE), and Serious Unexpected Serious Adverse Reactions (SUSAR). | Group A | Grade 2 or higher Adverse Events Related to Romidepsin | 29 | events | |
| Number of of Adverse Events (AE), Serious Adverse Events (SAE), and Serious Unexpected Serious Adverse Reactions (SUSAR). | Group B | Grade 2 or higher Adverse Events Related to Romidepsin | 5 | events | |
| Number of of Adverse Events (AE), Serious Adverse Events (SAE), and Serious Unexpected Serious Adverse Reactions (SUSAR). | Group A | Grade 2 or higher Adverse Events Related to 3BNC117 | 1 | events | |
| Number of of Adverse Events (AE), Serious Adverse Events (SAE), and Serious Unexpected Serious Adverse Reactions (SUSAR). | Group B | Grade 2 or higher Adverse Events Related to 3BNC117 | 0 | events | |
| Change in the Size of the Proviral HIV-1 Reservoir | Group A | 58 | Inter-Quartile Range 27 to 482 | HIV-1 DNA per million CD4+ T cells | |
| Change in the Size of the Proviral HIV-1 Reservoir | Group B | 46 | Inter-Quartile Range 0 to 270 | HIV-1 DNA per million CD4+ T cells | |
| Plasma HIV-1 RNA | Group A | 4 | Participants | ||
| Plasma HIV-1 RNA | Group B | 4 | Participants | ||
| HIV-1 Transcriptional Activity as Determined by Unspliced HIV-1 RNA (CA usHIV-1 RNA) in Circulating Total CD4+ T Cells. | Group A | 9 | Inter-Quartile Range 1 to 111 | CA-us HIV-1 RNA per million CD4 T cells | |
| HIV-1 Transcriptional Activity as Determined by Unspliced HIV-1 RNA (CA usHIV-1 RNA) in Circulating Total CD4+ T Cells. | Group B | 11 | Inter-Quartile Range 5 to 85 | CA-us HIV-1 RNA per million CD4 T cells |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02850016/results